公开(公告)号：WO2004048523A2

公开(公告)日：2004-06-10

申请号：PCT/US2003/037346

申请日：2003-11-21

Applicant: ISIS PHARMACEUTICALS, INC. ,  MONIA, Brett, P. ,  DOBIE, Kenneth, W. ,  PANASCI, Lawrence

Inventor： MONIA, Brett, P. ,  DOBIE, Kenneth, W. ,  PANASCI, Lawrence

IPC: C12N

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12N2310/3525

Abstract: Compounds, compositions and methods are provided for modulating the expression of Ku86. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Ku86. Methods of using these compounds for modulation of Ku86 expression and for diagnosis and treatment of disease associated with expression of Ku86 are provided.

Abstract translation: 提供化合物，组合物和方法用于调节Ku86的表达。 组合物包含针对编码Ku86的核酸的寡核苷酸。 提供了使用这些化合物调节Ku86表达和用于诊断和治疗与Ku86表达相关的疾病的方法。

公开(公告)号：WO2009082662A1

公开(公告)日：2009-07-02

申请号：PCT/US2008/087336

申请日：2008-12-18

Applicant: NOVARTIS AG ,  ALOYZ, Raquel Silvia ,  PANASCI, Lawrence Carl

Inventor： ALOYZ, Raquel Silvia ,  PANASCI, Lawrence Carl

IPC: A61K31/196 ,  A61K31/506 ,  A61K45/06 ,  A61P35/02

CPC classification number: A61K31/506 ,  A61K31/196 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to a combination which comprises (a) a DNA damaging agent; and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide ('nilotinib'); a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (CLL); the use of such a combination for the preparation of a medicament for the treatment of CLL; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.

Abstract translation: 本发明涉及一种组合，其包含（a）DNA损伤剂; 和（b）4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] -N- [5-（4-甲基-1H-咪唑-1-基）-3-（三氟甲基 ）苯基]苯甲酰胺（'尼洛替尼'）; 包含这种组合的药物组合物和任选的用于同时，分开或顺序使用，特别是用于治疗慢性淋巴细胞性白血病（CLL）的至少一种药学上可接受的载体; 使用这种组合来制备用于治疗CLL的药物; 包括这种组合的商业包装或产品; 以及治疗温血动物，特别是人的方法。

公开(公告)号：WO2004048523A3

公开(公告)日：2005-02-24

申请号：PCT/US0337346

申请日：2003-11-21

Applicant: ISIS PHARMACEUTICALS INC ,  MONIA BRETT P ,  DOBIE KENNETH W ,  PANASCI LAWRENCE

Inventor： MONIA BRETT P ,  DOBIE KENNETH W ,  PANASCI LAWRENCE

IPC: C12N5/02 ,  C12N15/113 ,  C12Q1/68 ,  A01N43/04 ,  C07H21/02 ,  C07H21/04 ,  C12N15/88 ,  C12P19/34

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12N2310/3525

Abstract: Compounds, compositions and methods are provided for modulating the expression of Ku86. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Ku86. Methods of using these compounds for modulation of Ku86 expression and for diagnosis and treatment of disease associated with expression of Ku86 are provided.

Abstract translation: 提供化合物，组合物和方法用于调节Ku86的表达。 组合物包含针对编码Ku86的核酸的寡核苷酸。 提供了使用这些化合物调节Ku86表达和用于诊断和治疗与Ku86表达相关的疾病的方法。

公开(公告)号：WO2004043466A1

公开(公告)日：2004-05-27

申请号：PCT/IB2003/005454

申请日：2003-11-10

Applicant: JEWISH GENERAL HOSPITAL ,  PANASCI, Lawrence, Carl ,  ALOYZ, Raquel, Silvia

Inventor： PANASCI, Lawrence, Carl ,  ALOYZ, Raquel, Silvia

IPC: A61K31/505

CPC classification number: A61K31/196 ,  A61K31/137 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

Abstract: The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide or uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4pyridin-3-yl)pyrimidin-2-ylamino)phenylJ-benzamide of formula (I) or a pharmaceutically acceptable salt thereof, the invention pertains to the use of said combination for the treatment chronic lymphocytic leukemia.

Abstract translation: 本发明涉及一种组合，其包含（a）选自苯丁酸氮芥，氯萘嗪，雌莫司汀，氮芥，氧氯化氮盐酸盐，奈韦溴铵，吩噻嗪，泼尼匹昔汀，曲伐沙星或尿嘧啶芥菜的氮芥类似物，（b）4-（4-甲基哌嗪 - 吡啶-1-基甲基）-N-（4-甲基-3-（4-吡啶-3-基）嘧啶-2-基氨基）苯基] - 苯甲酰胺或其药学上可接受的盐，本发明涉及所述 组合治疗慢性淋巴细胞性白血病。